Drug Profile
Gersizangitide - AsclepiX Therapeutics
Alternative Names: AXT-107Latest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator AsclepiX Therapeutics
- Class Eye disorder therapies; Peptides
- Mechanism of Action TIE-2 receptor agonists; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
Most Recent Events
- 19 Dec 2023 AsclepiX Therapeutics initiates enrolment in a phase I/II DISCOVER trial in Wet age-related macular degeneration in USA (Intravitreous) (NCT05859776)
- 26 Jul 2023 AsclepiX Therapeutics plans phase I/II DISCOVER trial for Wet age-related macular degeneration in January 2024 (Intravitreous) (NCT05859776)
- 28 Dec 2021 Phase-I/II clinical trials in Retinal vein occlusion (Intravitreous), prior to December 2021 (AsclepiX Therapeutics pipeline, December 2021)